Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 4,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) CFO Benjamin Hohl sold 4,250 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total transaction of $98,515.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

  • On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00.
  • On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50.
  • On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total transaction of $346,080.00.
  • On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $59,312.50.

Enliven Therapeutics Stock Up 5.7 %

NASDAQ:ELVN traded up $1.21 on Thursday, hitting $22.54. The stock had a trading volume of 157,297 shares, compared to its average volume of 257,784. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -11.80 and a beta of 1.05. The company has a fifty day moving average price of $20.41 and a two-hundred day moving average price of $16.14. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ELVN. Exchange Traded Concepts LLC grew its position in shares of Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after buying an additional 2,208 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at $66,000. Mirae Asset Global Investments Co. Ltd. grew its position in Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. Finally, AJOVista LLC purchased a new position in Enliven Therapeutics during the 4th quarter worth $28,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock.

Check Out Our Latest Report on Enliven Therapeutics

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Recommended Stories

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.